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Objectives: The proposed study aims to model patient-centric structural determinants of adherence
rates among asthma patients and explore the potential of mobile health apps such as the TRUSTR
platform to improve adherence using its power of monetary and non-monetary chatbotting and nonmonetary nudges. Following specific hypotheses are tested: (1) Patient attributes, such as their age and
medical condition, have significant effect on their adherence with the prescribed treatment plans. (2)
Behavioral nudging with rewards and engagement via mobile health apps will increase adherence rates.
Methods: The patient population (N = 37 359) consists of commercially insured patients with
asthma who have been identified from administrative claims in the HealthCore Integrated Research
Database (HIRD) between April 1, 2018 and March 31, 2019. Two Structural Equation Models
(SEMs) are estimated to quantify direct, indirect, and total effect sizes of age and medical condition on
proportion of days covered (PDC) and medical possession ratio (MPR), mediated by patient medical
and pharmacy visits. Fourteen additional SEMs were estimated to lateralize TRUSTR findings and
conduct sensitivity analysis.
Results: HIRD data reveal mean adherence rate of 59% (standard deviation (SD) 29%) for PDC
and 58% for MPR (SD 36%). Key structural findings from SEMs derived from the HIRD dataset
indicate that each additional year in the age of the patient has a positive total effect on the adherence
rate. Patients with poor medical condition are likely to have lower adherence rate, but this direct effect
is countered by mediating variables. Further, each additional reward and higher engagement with a
mobile app is likely to have a positive total effect on increasing the adherence rate.
Conclusions: HIRD data reveal mean adherence rate of 59% (SD 29%), providing the evidence for
the opportunity to increase adherence rate by around 40%. Statistical modeling results reveal structural
determinants, such as the opportunity to nudge, are higher among younger patients, as they have
higher probability of being non-adherent. Methodologically, lateralization approach demonstrates the
potential to capture real-world evidence beyond clinical data and merge it with clinical data.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International
License (CCBY-4.0). View this license’s legal deed at http://creativecommons.org/licenses/by/4.0 and legal code at
http://creativecommons.org/licenses/by/4.0/legalcode for more information.
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BACKGROUND AND OBJECTIVES
Asthma is reported to affect 20.4 million adults over 18 in the US
representing 8.3% of the adult population, with the number of newly
diagnosed cases rising annually (+28% between 2001 to 2011). Nearly
65% of adults with current asthma have persistent asthma accounting
for considerable asthma morbidity, mortality, and costs. Each day,
11 Americans die from asthma, and in 2015, 3615 people died from
asthma. Adults are four times more likely to die from asthma than
children.1 Lack of adherence with the prescribed medications by
asthma patients is a significant factor in increasing mortality rates from
asthma.2–6 Recent systematic review studies, however, have identified
that there are significant gaps in understanding behavioral and socioeconomic drivers of non-adherence with prescribed medications.7,8
While more quantitative studies are needed to understand the
impact of non-adherence on the survival probabilities of asthma
patients, improved understanding of the patient-centric structural
determinants of adherence to prescribed treatments may provide
actionable information to policy makers and relevant public and
private sector stakeholders about the leverage points to maximize
adherence rates among asthma patients accounting for their age,
medical condition and the process of treatment (ER, hospitalization,
specialist etc.). Furthermore, testing the impact of novel interventions
to improve adherence rates, such as behavioral nudging through mobile
health applications, could be more rigorously evaluated if the patientcentric structural determinants of variable adherence rates among
asthma patients are better understood.
Fewer than 10% of all asthma clinical trials have included patient
reported outcomes (PROs) while delivering more patient-centered
care is the common objective of the industry. To reach the highest
standard of patient-centered care, the deployment of engagement
solutions, including the collection of PROs and patient insights during
treatments, must be a priority. Combining objective and subjective
measures can capture patient insights and experiences and predict
patients’ long-term treatment outcomes, health status, quality of life,
and provide a better understanding of the parameters of adherence
for each patient. While engaging with patients during treatment has
been a challenge in the past, new health mobile app technologies like
TRUSTR can easily engage with patients during their treatment with
very high response rates, and a continuous flow of both self-reported
and wearable-corroborated data with AI chatbotting, nudge theory,
and conversational surveys. This study aims to estimate the capacity
of such technology to engage with patients, collect patient insights
and PROs, and improve adherence in a real-world setting accounting
for patient-centric structural determinants of adherence rates.
Text messages have been shown to be highly effective and costeffective at reaching patients outside of the hospital setting. Recently,
there has been great interest in the “beyond the pill” or “beyond the
point of infusion” area of the conversational patient experience. These
include daily reminders to stay adherent or the offering of personalized
motivational texts that can include words of recognition. Each of these
touch points can augment treatment experience in a positive way, such as
improving adherence rates, to be interpreted in their aggregate toward a
wide range of value added for public and private sectors. Han and Lee9
conducted a systematic review of 20 randomized, controlled trial (RCT)
studies to examine the effectiveness of mobile health applications in
changing health related behaviors and clinical health outcomes. They
found that 16 out of these 20 studies reported a positive impact on the
targeted health behavior or clinical health outcomes. These RCT studies
focused on evaluating the impact of mobile health apps on changing
health related behaviors such as physical activity,10,11 adherence rate,12,13
dietary change,14 weight loss,15,16 smoking cessation,17 and alcohol

addiction.18 Another meta-analysis study19 evaluated 9 RCTs with
1159 subjects to quantify efficacy of app-based interventions designed
to support medication adherence and investigate which behavior
change techniques used by the apps are associated with efficacy. In
the sampled RCTs, health conditions of target populations included
cardiovascular disease, depression, Parkinson’s disease, psoriasis, and
multimorbidity. This study found that patients who use mobile apps
to support them in taking medications are more likely to self-report
adherence to medications. However, the meta-regression of behavioral
change techniques did not reveal any significant associations with the
effect size.
In this evolving socio-technological context, alongside text
conversations, identifying activity levels using wearable tracking
devices highlights an opportunity to collect persistent, intelligent
patient reported outcomes (iPROs) by merging conversational chatbots
with wearable-corroborated measurements. Continuous motivated
adherence to medication and early reporting of treatable side effects
are high priority areas of interest. Mobile health apps such as TRUSTR
can potentially measure the treatment experience using the power
of chatbotting, nudge theory, conversational surveys, and wearablecorroborated data in a real-world setting.
This study models patient-centric structural determinants of
adherence rates among asthma patients and explores the potential of
mobile health apps such as TRUSTR platform to improve adherence
using its power of chatbotting, monetary and non-monetary nudges,
and conversational surveys. The identification of key variables and
tendencies will help practitioners describe, understand, and predict the
outcomes of a real-world setting use of TRUSTR in the population
of interest. It will also yield insights into ways by which to improve
patient adherence and patient satisfaction. The following two specific
hypotheses are tested in this study:
1.

2.

Patient attributes, such as age and medical condition, have
significant effect on their adherence with the prescribed treatment
plans:
a. Older patients are more likely to have higher adherence rates
than younger patients and
b. Patients suffering from severe medical conditions are likely
to have lower adherence rate, and
Compared with a non-TRUSTR lateralized database control,
behavioral nudging with rewards and engagement through
chatbotting through mobile health apps such as TRUSTR will
increase adherence rates.

METHODS
Measurement of Adherence Rates
Adherence rate is generally measured using two approaches: medical
possession ratio (MPR)20–22 and proportion of days covered (PDC).6,23–
25
There is no single statistical definition for MPR and various MPR
calculations have been developed and discussed in the literature.26 The
MPR value determines the proportion of days of medication supply
within a time interval and both fixed and variable time intervals have
been used. We used a variable time interval to accommodate covariance
analysis described in SEM methodology. Specific definitions of MPR
and PDC used in this study are provided as follows.
Medical possession ratio (MPR) is defined as the total number
of treated days in the specified time period divided by total number of
days from first treated day until the last treated day (including the last
Rx day supply). In this study, MPR is only calculated among patients
that have two or more fills with the specified medications over the
specified period; MPR of patients with only one fill with the specified
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medications is coded as ‘0’.
MPR =

total Rx days of supply
total days in observation period from first until last treated day

PDC uses all available data for a given patient (i.e. from index
until the end of continuous eligibility) and is calculated as the total
number of covered days on a medication during the time period from
index until the end of study observation period, divided by the total
number of days in observation period from first until last treated day.
PDC=

total covered days on drug(s) in study period
total days in observation period from first until last treated day

We used both measures, MPR and PDC, with variable time
measures to estimate the adherence rate in this study.
Patient-Centric Data of Adherence Rates Among Asthma Patients
The data source for this study is the HealthCore Integrated Research
Database® (HIRD). The HIRD is a large administrative health care
database maintained by HealthCore for use in health outcomes and
pharmacoepidemiologic research. The HIRD contains a broad, clinically
rich and geographically diverse spectrum of longitudinal medical and
pharmacy claims data from 14 Anthem-affiliated health plans in the
Northeastern, Mid-Atlantic, Southeastern, Midwest, Central, and
Western regions of the United States and represents members in each
of the 50 states. The database includes lines of business such as health
maintenance organizations, point of service plans, preferred provider
organizations, Medicare Advantage, consumer directed health plans,
and indemnity plans. HIRD data on over 49 million patients are
available from January 1, 2006, for all of the plans represented in the
database.
For the HIRD sample presented in this study, the patient
identification period is from April 1, 2018 to March 31, 2019 and
patients are required to have continuous enrollment during that period.
The sampled patient population consists of commercially insured
patients with asthma who have been identified from administrative
claims in the HIRD between April 1, 2018 to March 31, 2019 (patient
identification period) and meet the following inclusion criteria:
1.

2.

3.
4.
5.

At least one medical claim with an ICD-10-CM diagnosis code
for moderate or severe persistent asthma (J45.4x or J45.5x)
during the patient identification period from April 1, 2018, to
March 31, 2019,
At least one pharmacy claim for an inhaled corticosteroid (ICS)
or at least one pharmacy claim for a long-acting beta-2 adrenergic
agonist (LABA) or at least one pharmacy claim for an ICS/LABA
combo medication (See Supplementary Materials, Table S2 for
specific medication names and generic product identifier codes),
Have only commercial health insurance during April 1, 2018, to
March 31, 2019,
Are 18 years of age or older as of the end of the patient
identification period (March 31, 2019), and
Have at least 12 months of continuous enrollment with both
medical and pharmacy benefits during the patient identification
period.

The number of patients, means, SD, standard errors (SE),
medians, correlation and covariance matrices were provided for ten
asthma-related claims-determined variables described in Table 1 for
the patient identification period from April 1, 2018, to March 31,
2019. All study measures of interest were described using univariate

statistics consisting of number of patients, mean, SD, SE, and median.
The patient cohort was limited to patients with at least one medical
claim with an ICD-10-CM asthma diagnosis in any position and at
least one pharmacy claim for an ICS, LABA, or ICS/LABA combo
medication in the 12 month period from April 1, 2018 to March 31,
2019. The correlation and covariance matrices for the study measures
were determined for the identified patient cohort; all study variables
were considered to be continuous and there were no missing values for
any of them. All variables were included, except inpatient length of stay
(LOS), which was presented descriptively since it was calculated only
for those patients with at least one inpatient hospitalization. Table 2
and Table 3 show means, variances, and covariances of 10 variables that
were used to estimate Summary Statistics Data (SSD) in STATA 15.
SEMs Estimated from Summary Statistics Databases (SSDs)
STATA 15 SSD commands were used to reconstruct the dataset and
measure 16 SEMs. SEMs #1 and #2 were measured to predict MPR and
PDC respectively directly from the HIRD dataset. Data analysis was
performed using structural equation modeling logarithms in STATA
15 for Windows (StataCorp LLC, College Station, TX) specifically
following SEM algorithms developed by Acock28 and Ullman and
Bentler.29
Goodness-of-fit statistics were used to determine the fit of the
estimated SEMs to the sample data. Two approaches to measure the
goodness of fit were utilized for evaluating the model fit of estimated
SEMs: Standardized Root Mean-squared Residual (SRMR) and
Coefficient of Determination (CD). Ideally, the best fit models have
SRMR closer to zero and CD closer to one. SRMR and CD for all 16
SEMs are reported in the Supplementary Materials. Since SEMs were
derived from SSD, we could not use other statistics (e.g., likelihood
ratio tests, comparative fit index, Tucker-Lewis index) to evaluate the
model fitness.
Lateralization of TRUSTR Social Media Experimental Findings
to Modeling Patient-Centric Adherence Rates
Tables 2 and 3 show the addition of two variables (shown in red
font), rewards [measured as $/month] and engagement rate [measured
as text messages/month] that were lateralized from TRUSTR social
media study (see Zia et al27) to explore the potential of mobile health
apps on adherence rates. We assume that rewards are distributed with a
mean of $30 per month and SD of $15. We assume baseline covariance
rates of 0.7 and 0.6 between rewards and MPR, and PDC respectively.
Further, we assume that respondents send a mean of 234 text messages
per month with an SD of 180 messages per month. Consistent with the
social media study, we assume a high covariance of 0.82 between rewards
and engagement rate. We also assume baseline covariance rates of 0.5
and 0.46 between engagement rate and MPR, and PDC respectively.
Four sensitivity analysis scenarios are also tested, with two scenarios (S1
and S2) representing 10% and 20% increases in covariance of rewards
and engagement rate with adherence rate measures (MPR and PDC),
and two scenarios representing 10% and 20% decreases in covariance
of rewards and engagement rate with adherence rate measures (See
Table 4 for scenarios representing sensitivity analysis). SEMs #3 and
#4 measure the effect of rewards on MPR and PDC respectively; SEMs
#5 and #6 measure the effect of engagement rate on MPR and PDC
respectively; and SEMs #7 and #8 measure the effect of both rewards
and engagement rate on MPR and PDC respectively. Finally, we
present results of sensitivity analysis through eight additional SEMs,
four of which vary covariance between rewards and engagement rate
vis-à-vis adherence rate measure of MPR, and the other four for PDC
by 10% and 20% increases or decreases in covariance, compared with
baseline covariance rates assumed in SEMs #7 and #8.
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Table 1. Study Variables
Name in the Protocol

Name in the Model Code

Description

Age

age

Age in years at end of patient identification period.

Inpatient Hospitalizations

inpatient_hospitaliza~s

Number of inpatient hospitalizations (including ER visits that lead
to a hospitalization); no inpatient hospitalization is coded as ‘0’
LOS among patients with >1 asthma-related hospitalization;
aggregated over period of interest (days), mean (SE), median.

ER Visits

er_visits

Number of ER visits; no ER visit is coded as ‘0’.

Primary Care Physician (PCP) [Family
Medicine/Practice, Internal Medicine,
Gerontologist] Office Visits

pcp_officevisits

Number of Primary Care Physician (PCP) [Family Medicine/
Practice, Internal Medicine, Gerontologist] office visits; no visit is
coded as ‘0’.

Specialist (Allergy/Immunology,
Pulmonology, Respiratory) Office Visits

specialist_office_vis~s

Number of Specialist (Allergy/Immunology,
Respiratory) office visits; no visit is coded as ‘0’.

Other Outpatient Services

other_outpatientservi~s

Number of other outpatient services (e.g., durable medical
equipment, imaging, medication and related services, procedures,
physical therapy/occupational therapy/speech, physician other
services, lab tests, other); no other outpatient services is coded as
‘0’.

Asthma-Related Pharmacy Dispensing

pharmacy_fills

Asthma-related pharmacy dispensing (n[%] of patients with
≥1 prescription fill for all medications listed in Supplementary
Material, Table S2; mean [SE]/median of fills among all patients)
(refer to Supplementary Material, Table S2 for codes).

Medical Possession Ratio (MPR)

mpr

Medical possession ratio (MPR) for ICS, LABA, and ICS/LABA
combo medications (n[%] of patients with ≥1 prescription
fill; mean [SE]/median of fills among all patients) (refer to
Supplementary Material, Table S2 for codes). MPR is defined as
total number of treated days in the specified time period divided by
total number of days from first treated day until the last treated day
(including the last Rx day supply). MPR is only calculated among
patients that have two or more fills with the specified medications
over the specified period; MPR of patients with only one fill with
the specified medications is coded as ‘0’.

Proportion of Days Covered (PDC)

pdc

Proportion of days covered (PDC) for ICS, LABA, and ICS/
LABA combo medications (n[%] of patients with ≥1 prescription
fill; mean [SE]/median of fills among all patients) (refer to
Supplementary Materail, Table S2 for codes). PDC is defined as
total number of treated days in the specified time period divided
by total number of days from first treated day until the end of the
period. Calculated only among those patients who received one or
more of the specified medication(s) over the specified period.

Quan-Charlson Comorbidity Index
(QCI) score

qci_score

Quan-Charlson comorbidity index (QCI) score; n of patients;
mean (SE), median (refer to Supplementary Material, Table S3 for
codes)

Pulmonology,

To quantify comorbidity, the QCI score is computed by adding
the weights that are assigned to the specific diagnoses. A score of
1 is attributed to myocardial infarction, congestive heart failure,
peripheral vascular disease, cerebrovascular disease, dementia,
chronic pulmonary disease, connective tissue/rheumatologic
disease, peptic ulcer disease, mild liver disease, and diabetes without
chronic complications. The following diseases are scored as 2:
hemiplegia or paraplegia, renal disease, diabetes with complications,
and malignancy including leukemia and lymphoma. Moderate or
severe liver disease is scored 3. Finally, a score of 6 is assigned to
metastatic solid carcinoma and AIDS/HIV. Each diagnosis is only
counted once (e.g., if a patient has ICD-9 code 410.xx and 412.xx,
they will receive a score of 1 for MI, not 2). The minimum possible
score is 0 and the maximum possible score is 33.
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Table 2. Means and Medians for HIRD Data and Two Lateralization Variables, Rewards, and Engagement Rate Derived from the
TRUSTR Social Media Study27
Number (n%)

Analysis
Sample Size

Mean

SD

SE

Median

37 359 (100.0%)

37 359

49.64

14.87

0.0769

52

1133 (3.0%)

37 359

0.04

0.26

0.0013

0

1133 (3.0%)

1133

5.61

6.80

0.2020

4

ER Visits

684 (1.8%)

37 359

0.02

0.20

0.0010

0

Out visits

36 789 (98.5%)

37 359

3.18

4.73

0.0245

2

PCP Office Visits

12 883 (34.5%)

37 359

2.18

2.50

0.0129

1

Specialist Office Visits

18 987 (50.8%)

37 359

2.61

3.81

0.0197

2

Other Outpatient Services

26 740 (71.6%)

37 359

2.22

4.41

0.0228

1

Pharmacy Fills (All meds in table 2)

37 359 (100.0%)

37 359

9.95

7.37

0.0381

8

Pharmacy Fill (ICS, LABA, ICS/LABA)

37 359 (100.0%)

37 359

10 571 (28.3%)

37 359

371 (1.0%)

37 359

30 590 (81.9%)

37 359

Quan-Charlson Comorbidity Index
(QCI) score

37 359 (100.0%)

37 359

1.47

1.13

0.0058

1

MPR (ICS, LABA, ICS/LABA)

37 359(100.0%)

37 359

0.58

0.36

0.0019

0.66

PDC (ICS, LABA, ICS/LABA)

37 359 (100.0%)

37 359

0.59

0.29

0.0015

0.60

Reward

37 359

37 359

30

15

0.1

35

Engagement rate (messages/month)

37 359

37 359

234

180

0.18

265

Variable
Age on 03/31/2019
Inpatient Hospitalizations
Length of Stay (LOS) among
patients with >1 asthma-related
hospitalization

ICS Monotherapy
LABA
ICS/LABA combination
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Table 3. Variance and Covariances of HIRD and Lateralized Data

QCI Score

Age

ER Visits

221.105233

0.089650

-0.094017

2.442816

3.267802

5.864529

14.209445

4.632682

0.803770

0.761121

Inpatient Hospitalization

0.089650

0.067846

0.011868

0.037303

0.033255

0.113002

0.200045

0.036237

0.000065

-0.000166

ER Visits

-0.094017

0.011868

0.040578

0.033435

0.022245

0.075032

0.084031

0.002199

-0.001100

-0.000795

PCP Office Visits

2.451662

0.037385

0.033620

6.244202

6.816085

7.943561

4.400360

0.101140

0.087750

0.047842

Specialist Office Visits

3.267802

0.033255

0.022245

6.805591

14.548804

15.837080

7.174931

0.076749

0.131478

0.073374

Outpatient Services

5.864529

0.113002

0.075032

7.918511

15.837080

22.331055

10.065882

0.274862

0.182628

0.105173

Pharmacy (Asthma meds)

14.209445

0.200045

0.084031

4.385411

7.174931

10.065882

54.346633

0.771759

1.037027

0.708629

QCI Score

4.632682

0.036237

0.002199

0.101364

0.076749

0.274862

0.771759

1.282943

0.018688

0.012082

MPR (ICS, LABA, ICS/
LABA)

0.803770

0.000065

-0.001100

0.087459

0.131478

0.182628

1.037027

0.018688

0.129239

0.062483

PDC (ICS, LABA, ICS/
LABA)

0.761121

-0.000166

-0.000795

0.047573

0.073374

0.105173

0.708629

0.012082

0.062483

0.082140

-0.2

-0.8

-0.6

0.05

0.1

0.15

0.85

0.002

0.7

0.6

225

-0.100000

-0.600000

-0.7

0.08

0.2

0.26

1.04

0.001

0.5

0.46

0.82

Age

Rewards
Engagement rate
(messages/month)

Outpatient
Services

PDC
(ICS, LABA, ICS/
LABA)

Inpatient
Hospitalization

Specialist
Office Visits

Pharmacy
(Asthma
meds)

MPR
(ICS,
LABA,
ICS/LABA)

PCP
Office
Visits

ER=Emergency Room; PCP=Primary Care Physician; QCI=Quan-Charlson Comorbidity Index; MPR=Medication Possession Ratio; PDC=Proportion of Days Covered
ICS=Inhaled corticosteroid; LABA=Long acting beta-2 adrenergic agonist
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Table 4. Scenarios Representing Sensitivity Analysis on
Covariance of Rewards and Engagement Rate With Adherence
Rate Measures (MPR and PDC)
Senstivity analysis BASELINE
MPR

PDC

Rewards

0.7

0.6

Engagement Rate

0.5

0.46

Senstivity analysis 10% higher covariance (S1)
MPR

PDC

Rewards

0.77

0.66

Engagement Rate

0.55

0.506

Senstivity analysis 20% higher covariance (S2)
MPR

PDC

Rewards

0.84

0.72

Engagement Rate

0.6

0.552

Senstivity analysis 10% lower covariance (S3)
MPR

PDC

Rewards

0.63

0.54

Engagement Rate

0.45

0.414

Senstivity analysis 20% lower covariance (S4)
MPR

PDC

Rewards

0.56

0.48

Engagement Rate

0.4

0.368

RESULTS
Estimated SEMs for eight models are presented in the Supplementary
Material (Appendix 2). The direct, indirect, and total effects of each
SEM are also presented in the Supplementary Material (Appendix
2). Furthermore, results from eight additional SEMs estimated for
four sensitivity analysis scenarios are reported in the Supplementary

Material (Appendix 3), and their highlights are also summarized.
Next, we focus on presenting the key findings with respect to the study
objectives and hypotheses.
Figure 1 and Figure 2 show statistically significant paths estimated
for SEMs 1 and 2, respectively.
Both of these SEMs show confounding effects of patient age
and QCI score on MPR and PDC. Both models predict that each
additional year in the age of the patient has a direct positive effect on
the adherence rate. Age also influences adherence rate through various
indirect pathways, as shown in Figures 1 and 2. Older people are less
likely to have inpatient hospitalizations and ER visits (connected with
asthma), and asthma patients going through inpatient hospitalizations
and ER visits are likely to have lower adherence rates (both MPR and
PDC). Conversely, older people are more likely to maintain their
pharmacy fills, which in turn has a positive effect on adherence rates.
Further, we also find that older people are more likely to engage in
PCP office visits, specialist office visits, and utilize other outpatient
services, but we do not detect any significant effect of these mediating
variables on adherence rates (with the exception of PCP office visits
having positive effect on MPR). When we combine direct and indirect
effects, age has consistently positive effect on adherence rate, implying
that younger people are less likely to adhere with prescribed asthma
medications (see Table 5 for total effects of eight SEMs).
Similarly, medical condition of the patients, measured through
QCI, also have confounding effects on adherence rates, mediated
through variegated health management pathways. Structural analysis in
Figures 1 and 2 also shows that, as expected, patients with worse medical
conditions are more likely to engage in inpatient hospitalizations, ER
visits, PCP office visits and other outpatient services, which in turn
have differential effects on adherence rates. The direct effects of medical
conditions on adherence rates are statistically significant in both SEMs:
patients with worse medical conditions are less likely to adhere. Overall,
from total effects analysis shown in Table 5, we find that patients with
worse medical condition (depicted by higher QCI score) have lower
adherence rate (significant for PDC at p<0.05, but not significant for
MPR).
Six additional SEMs were estimated to lateralize TRUSTR

Figure 1. SEM #1 Presents Structural Determinants of MPR from HIRD Data

Age

SEM #1

Inpa�ent
hospitaliza�ons

-.01**

Posi�ve eﬀect
-.03***

-.03***
.06***
.05***

ER visits
.01***
PCP oﬃce
visits

.27***

Nega�ve eﬀect

-.02***
.1***
.01**
MPR

.12***
.02***
QCI Score

.07***

.03***
.06***

.11***

-.01**

Specialist
oﬃce visits
Other
Outpa�ent
Services

.38***

Pharmacy
ﬁlls
Only statistically significant paths are shown.
* 90% confidence level; ** 95% confidence level; *** 99% confidence level
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findings (i.e., “what if ” scenarios tested to quantify impacts of
TRUSTR rewards and engagement nudges on behavioral change
from one population (social media) to another population (HIRD)).
Supplementary Materials show results for SEMs #3 through #6. Here,
in Figure 3 and Figure 4 we show results from SEMs #7 and #8, each
of which presents structural determinants for variables derived from
HIRD data set as well as TRUSTR variables (rewards and engagement
rate) that are hypothesized to influence adherence rates as mediated
through health management pathways. Table 5 presents total effects
for all eight SEMs. Further, sensitivity analysis around lateralization
assumptions were conducted with eight additional SEMs, results of
which are shown in Table 6.
From Figures 3 and 4 and Table 5, we find that with lateralization,
age has a consistently significant positive effect size across both MPR

and PDC; however, QCI score has a negative effect only for PDC.
Importantly, we find that each additional monetary reward increases
the likelihood of adherence rate. The total effect of engagement rate
is marginally positive for PDC but insignificant for MPR. Further,
sensitivity analysis results shown in Table 6 demonstrate that generally
the findings about structural determinants of adherence rates are
robust across SEMs. The effects of rewards and engagement rate
however predictably vary upward and downward, when we marginally
increase (SEMs #9 through #12) or marginally decrease (SEMs #13
through #16) the covariance between rewards and adherence rates
or engagement rates and adherence rates. Remaining structural
determinants of adherence rates retain the direction and magnitude of
their effects, as estimated in SEMs #1 through #8.

Figure 2. SEM #2 Presents Structural Determinants of PDC from HIRD Data

Age

SEM #2

Inpa�ent
hospitaliza�ons

-.01**

Posi�ve eﬀect
-.03***

-.03***
.06***
.05***

ER visits

-.02***

.01***
PCP oﬃce
visits

.27***

Nega�ve eﬀect

.14***

PDC
.12***
.02***
QCI Score

.07***

.03***
.06***

.11***

-.02***

Specialist
oﬃce visits
Other
Outpa�ent
Services

.32***

Pharmacy
ﬁlls
Only statistically significant paths are shown.
* 90% confidence level; ** 95% confidence level; *** 99% confidence level

Table 5. Comparison of Total Effects Across Eight SEMs
Predictor

SEM #1
(MPR)

SEM #2
(PDC)

SEM #3
(MPR)

SEM #4
(PDC)

SEM #5
(MPR)

SEM #6
(PDC)

SEM #7
(MPR)

SEM #8
(PDC)

Inpatient
hospitalizations

-0.0340***

-0.0303***

-0.0120**

-0.0060

-0.0339***

-0.0302***

-0.0120**

-0.0059

ER visits

-0.0259***

-0.01914***

-0.0055

0.0034

-0.0258***

-0.0190***

-0.0054

0.0035

PCP office visits

0.01583**

-0.0006***

0.0136**

-0.0031

0.0158**

-0.0007

0.0136*

-0.0031

Specialist office
visits

-0.0107

-0.0093

-0.0014

0.0008

-0.0106

-0.0093

-0.0014

0.0008

Other Outpatient
Services

-0.0078

-0.0154

-0.0174*

-0.0259**

-0.0078

-0.0154

-0.0174*

-0.0260**

Pharmacy fills

0.3844***

0.3293***

0.3812***

0.3257***

0.3844***

0.3293***

0.3812***

0.3257***

Age

0.1486***

0.1451***

0.1489***

0.1818***

0.1486

0.1815***

0.1489***

0.1818***

0.0048

-0.0283***

0.0048

-0.0129**

0.0048965

-0.0128**

0.0048

-0.0129**

Rewards

N/A

N/A

0.1297***

0.1393***

N/A

N/A

0.1297***

0.1393***

Engagement Rate

N/A

N/A

N/A

N/A

0.0077

0.0088*

0.0076

0.0088*

QCI Score

* 90% confidence level; ** 95% confidence level; *** 99% confidence level
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Figure 3. SEM #7 Presents Structural Determinants of MPR from HIRD Data and TRUSTR Social Media Experimental Data
-.01**

Age

SEM #7

Inpa�ent
hospitaliza�ons

.12***

Posi�ve eﬀect
-.01**

Nega�ve eﬀect

ER visits

.27***
QCI Score

PCP oﬃce
visits

.11***

.01**

-.01**
-.2***
-.19***

Specialist
oﬃce visits

Rewards

-.01**
Engagement
Rate

MPR

.12***

Other
Outpa�ent
Services

.1***

-.01**

-.01**
.38***

Pharmacy
ﬁlls

Only statistically significant paths are shown.
* 90% confidence level; ** 95% confidence level; *** 99% confidence level

Figure 4. SEM #8 Presents Structural Determinants of PDC from HIRD Data and TRUSTR Social Media Experimental Data
-.01**

Age

.12***
.11***

.27***

SEM #8

Inpa�ent
hospitaliza�ons

QCI Score

Posi�ve eﬀect
Nega�ve eﬀect

ER visits

.14***

PCP oﬃce
visits

-.03**
-.2***
-.19***
Rewards

-.01**
Engagement
Rate

-.01**

PDC

.13***
Specialist
oﬃce visits
Other
Outpa�ent
Services

.008*
-.02**
.32***

Pharmacy
ﬁlls

Only statistically significant paths are shown.
* 90% confidence level; ** 95% confidence level; *** 99% confidence level
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Table 6. Sensitivity Analysis: Total Effects on Adherence Rate for Four Scenarios
SEM #9
(MPR)
S1: 10% ↑

SEM #10
(PDC)
S1: 10% ↑

SEM #11
(MPR)
S2: 20% ↑

SEM #12
(PDC)
S2: 20% ↑

SEM #13
(MPR)
S3: 10% ↓

SEM #14
(PDC)
S3: 10% ↓

SEM #15
(MPR)
S4: 20% ↓

SEM #16
(PDC)
S4: 20% ↓

Inpatient
hospitalizations

-0.0095*

-0.0032

-0.007

-0.0005

-0.0145**

-0.0086*

-0.0169***

-0.0112**

ER visits

-0.0030

0.0060

-0.0007

0.0085*

-0.0077

0.0010

-0.0010**

-0.0014

PCP office visits

0.0134**

-0.0033

0.0131*

-0.0036

0.0139**

-0.0028

0.0141**

-0.0025

Specialist office
visits

-0.0003

0.0019

0.0006

0.0031

-0.0024

-0.0002

-0.0035

-0.0013

Other Outpatient
Services

-0.0185*

-0.02720**

-0.0196*

-0.0283**

-0.0163

-0.0248**

-0.0152

-0.0237**

Pharmacy fills

0.3809***

0.3253***

0.3805***

0.3249***

0.3816***

0.3261***

0.3819***

0.3265***

Age

0.1489***

0.1818***

0.1489***

0.1818***

0.1488***

0.1817***

0.1488***

0.1817***

0.0048

-0.0129**

0.0048

-0.0129**

0.0048

-0.0128**

0.0048

-0.0128**

0.1427***

0.1532***

0.1557***

0.1672***

0.1167***

0.1254***

0.1038***

0.1115***

0.0084*

0.0097*

0.0092*

0.0106**

0.0069

0.0079

0.0061

0.0070

Predictor

QCI Score
Rewards
Engagement Rate

* 90% confidence level; ** 95% confidence level; *** 99% confidence level

DISCUSSION
HIRD data reveal a mean adherence rate of 59% (SD 29%), providing
the evidence for the opportunity to increase adherence rate by around
40%. Specifically, HIRD data reveal mean adherence rate of 59% (SD
29%) for PDC and 58% for MPR (SD 36%). While PDC is typically
considered to be more conservative estimate of medication adherence
rate compared with MPR, the HIRD dataset reveals statistically similar
mean value. The SD of MPR is however higher than PDC. The reason
the mean MPR is slightly less than the mean PDC is because of the
statistical definition of MPR that we used. As indicated earlier, there is
no single statistical definition for MPR and various MPR calculations
have been developed and discussed in the literature.26 The MPR value
determines the proportion of days of medication supply within a time
interval and both fixed and variable time intervals have been used.
We used a variable time interval—the MPR denominator, is the total
number of days from first treated day until the last treated day. This
requires at least two fills and patients with only one fill were coded
with an MPR of zero so that all 37 359 observations could be used for
the covariance calculations. The statistical MPR and PDC definitions
that were used are given in Table 1. The effect of the zero MPR’s on the
mean reduces the mean MPR so that it is less than the average PDC;
however, the median is unaffected by the 0 MPRs and the median
MPR (0.66) > median PDC (0.60) (see Table 2).
A key implication of this study is that statistical modeling
results reveal structural determinants, which could be utilized to find
substantial opportunities for increasing the adherence rates. First,
structural analysis of HIRD data set reveals that the opportunity to
nudge is higher among younger patients as they have higher probability
of being non-adherent. Second, patients with relatively worse medical
conditions could also be targeted for improving the overall adherence
rates with asthma medications.
Findings about structural determinants of adherence rates are
also consistent with previously published empirical literature. For
example, in a recent systematic review of 51 published studies focused
on evaluating asthma inhaler adherence determinants in adults, Dima
et al7 found “consistent links between adherence and stronger inhalernecessity beliefs, and possibly older age.” While our study did not
explicitly model inhaler-necessity beliefs, as these are not available
in HIRD data set, we found statistically significant effect of age on
adherence, consistent with Dima et al.7 finding. Similar age effects on

adherence rates were found by Feehan et al.6 Further, our structural
findings about patient medical condition and health management
interventions are also consistent with previous literature reviewed
by Bårnes and Ulrik.5 A review of 19 studies revealed that the mean
level of adherence was between 22% and 63%. “Poor adherence was
associated with youth, being African-American, having mild asthma,
<12 years of formal education, and poor communication with the
health-care provider, whereas improved adherence was associated with
being prescribed fixed-combination therapy (ICS and long-acting beta2 agonists). Good adherence was associated with higher FEV1, a lower
percentage of eosinophils in sputum, reduction in hospitalizations,
less use of oral corticosteroids, and lower mortality rate (Bårnes and
Ulrik5).”
Lateralization of structural findings from HIRD dataset, when
merged with TRUSTR social media experimental study, identify
potential pathways to capitalize on the opportunities available for
targeting younger asthma patients and/or patients in relatively worse
off medical condition. In our lateralization approach, we assumed
fairly conservative assumptions, and then conducted sensitivity
analysis around those conservative assumptions, and discovered that
each additional TRUSTR reward has a positive total effect on nudging
the adherence rate to be higher. Since many mobile health app studies
have found evidence in the literature that younger people are more
likely to use mobile health apps, deployment of mobile health apps to
nudge the behaviors of younger people to be more complaint appears
very promising.30–35 An RCT with a mobile health app (e.g., TRUSTR)
would be the next logical step to test the potential of nudging younger
asthma patients to become more adherent with their medications. In
a recently published meta-analysis study, Armitage et al.19 found that
mobile health apps increase medication adherence rates among the
patients suffering from cardiovascular disease, depression, Parkinson’s
disease, psoriasis, and multimorbidity. This study shows that similar
benefits from mobile health apps could be derived for asthma patients.
The nudging opportunity might not be as straightforward with
the people suffering from relatively worse medical condition. Mere
provision of rewards might not be enough to overcome the capacity
limitations of severe asthmatic patients. Non-monetary nudging
through conversational features of mobile health apps could however
be tested in follow up RCT. Engaging younger patients through
conversational and non-monetary engagement could also be tested in
follow up RCTs. Existing telehealth applications fail to reach many
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patients, and fail to establish crucial elements of digital trust. Moreover,
many concerns of patients from a real-world data perspective are missed
by surveys that have very narrow response windows. The TRUSTR tool
allows for multichannel controlled messaging while inviting crucial
feedback in the patient’s own words. Moreover, by co-synchronizing
and co-registering with wearables and other applications (WhatsApp,
GoogleFit etc.), it is envisaged that TRUSTR can provide controlled
and validated information, asynchronously, just as it collects valuable
real-world data.

6.

CONCLUSIONS

9.

This study models patient-centric structural determinants of adherence
rates among asthma patients and explores the potential of mobile
health apps such as TRUSTR platform to improve adherence. The US
nationally representative HIRD data reveal mean adherence rate of
59% (SD 29%) for PDC and 58% for MPR (SD 36%). Key structural
findings from SEMs derived from the HIRD dataset indicate that: (1)
Each additional year in the age of the patient has a positive total effect
on the adherence rate. (2) Patients with worse medical condition (ie,
higher QCI score) are likely to have lower adherence rate, but this
direct effect is countered in opposite direction by mediating variables.
Further, key findings from lateralization of TRUSTR with HIRD
data indicate that: (3) Each additional reward has a positive total
effect on increasing the adherence rate. (4) Higher engagement rate
with TRUSTR app has a weak positive effect on increasing adherence
rate. These findings indicate that the opportunity to nudge is higher
among younger patients as they have higher probability of being
non-adherent. Methodologically, lateralization approach pioneered in
this study demonstrates the potential to capture real-world evidence
beyond clinical data and merge it with clinical data (e.g., this study
lateralizes TRUSTR experimental findings to a sample of 37 359
asthma patients identified from claims in the HealthCore Integrated
Research Database® (HIRD) using structural equation modeling
and path analysis). Statistical modeling demonstrates the ability to
differentiate patient behaviors of interest with more granularity (e.g.,
by age, medical condition (QCI score), and frequency of visits to ER,
specialists, PCPs, and other outpatient services). RCTs with mobile
health apps (e.g., TRUSTR) are recommended for future research
to test the potential of nudging (asthma) patients to become more
adherent with their medications.
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